GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS in collaboration with NINDS, Secures Rights

- Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide development rights
- GeNeuro launches pHERV-K Env antibody development program, aiming to reach IND by mid-2020

Geneva, Switzerland, October 17, 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced today that following a successful collaboration in preclinical amyotrophic lateral sclerosis (ALS) models, the Company has signed an exclusive worldwide license with the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH). The agreement covers the development of an antibody program to block the activity of pHERV-K Env (pathogenic envelope protein of the HERV-K family of Human Endogenous Retroviruses), a potential key factor in the development of ALS.

“We are happy that this collaboration with NINDS confirms the potential of GeNeuro’s pHERV-K antibodies in preclinical ALS models”, said Jesús Martín-Garcia, CEO of GeNeuro. The Company has now launched a preclinical development program for its pHERV-K Env antibody, with the objective of reaching an IND by mid-2020. “This step signals the potential for expansion of the GeNeuro clinical pipeline into additional neurological disorders.”

GeNeuro exercised its collaborator’s license option following positive results from studies of pHERV-K Env antibodies in preclinical ALS models conducted under the Cooperative Research and Development Agreement (CRADA) signed with the NINDS in January 2017.

“Following our work linking pHERV-K Env to ALS, the data from the work with GeNeuro provides the basis for a new therapeutic approach against this disease,” said Dr. Avindra Nath, clinical director at the National Institute of Neurological Disorders and Stroke.

“GeNeuro’s mission is to leverage its expertise in HERV biology to bring potential new treatments to patients, particularly in areas of high medical needs, such as ALS. We are fortunate and proud to have worked with the NINDS team led by Dr. Avindra Nath to maximize efficiencies and increase the chances of success for this new approach targeting pHERV-K Env,” said Hervé Perron, Chief Scientific Officer at GeNeuro.

About ALS

Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease or clinically as motor neuron disease, is a fatal, rapidly progressive neurodegenerative disease characterized by loss of motor neurons. The incidence of ALS is approximately 1-3 per 100,000 individuals and is consistent across diverse populations.

About GeNeuro

GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis and Type 1 Diabetes, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 28 employees and rights to 17 patent families protecting its technology.

For more information, visit: [www.geneuro.com](http://www.geneuro.com)

**Contacts:**

<table>
<thead>
<tr>
<th>GeNeuro</th>
<th>NewCap (France)</th>
<th>Halsin Partners</th>
<th>LifeSci Advisors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jesús Martin-Garcia</td>
<td>Emmanuel Huynh/</td>
<td>Mike Sinclair (media)</td>
<td>Chris Maggos (investors)</td>
</tr>
<tr>
<td>Chairman and CEO</td>
<td>Mathilide Bohin (investors)</td>
<td>+44 20 7318 2955</td>
<td>+1 646 597 6970</td>
</tr>
<tr>
<td>+41 22 552 48 00</td>
<td>Nicolas Mergeau (media)</td>
<td><a href="mailto:msinclair@halsin.com">msinclair@halsin.com</a></td>
<td>+41 79 367 6254</td>
</tr>
<tr>
<td><a href="mailto:investors@geneuro.com">investors@geneuro.com</a></td>
<td>+33 1 44 71 94 98</td>
<td><a href="mailto:geneuro@newcap.eu">geneuro@newcap.eu</a></td>
<td><a href="mailto:chris@lifesciadvisors.com">chris@lifesciadvisors.com</a></td>
</tr>
</tbody>
</table>

**Disclaimer:**

This press release contains certain forward-looking statements and estimates concerning GeNeuro’s financial condition, operating results, strategy, projects and future performance and the markets in which it operates. Such forward-looking statements and estimates may be identified by words, such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions. They incorporate all topics that are not historical facts. Forward looking statements, forecasts and estimates are based on management's current assumptions and assessment of risks, uncertainties and other factors, known and unknown, which were deemed to be reasonable at the time they were made but which may turn out to be incorrect. Events and outcomes are difficult to predict and depend on factors beyond the company’s control. Consequently, the actual results, financial condition, performances and/or achievements of GeNeuro or of the industry may turn out to differ materially from the future results, performances or achievements expressed or implied by these statements, forecasts and estimates. Owing to these uncertainties, no representation is made as to the correctness or fairness of these forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates speak only as of the date on which they are made, and GeNeuro undertakes no obligation to update or revise any of them, whether as a result of new information, future events or otherwise, except as required by law.